ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis
NASDAQ:ETON - US29772L1089 - Common Stock
17.67 USD
-0.2 (-1.12%)
17.67 USD
0 (0%)
Taking everything into account, ETON scores 4 out of 10 in our fundamental rating. ETON was compared to 195 industry peers in the Pharmaceuticals industry. ETON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ETON is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
ETON had negative earnings in the past year.
ETON had a positive operating cash flow in the past year.
ETON had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ETON reported negative operating cash flow in multiple years.
1.2 Ratios
ETON has a Return On Assets of -4.06%. This is in the better half of the industry: ETON outperforms 72.82% of its industry peers.
The Return On Equity of ETON (-17.23%) is better than 70.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.06% | ||
| ROE | -17.23% | ||
| ROIC | N/A |
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ETON (59.41%) is better than 66.67% of its industry peers.
ETON's Gross Margin has improved in the last couple of years.
ETON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
2. Health
2.1 Basic Checks
ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ETON has been increased compared to 1 year ago.
ETON has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ETON is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.07 indicates that ETON is not in any danger for bankruptcy at the moment.
ETON has a better Altman-Z score (3.07) than 72.31% of its industry peers.
The Debt to FCF ratio of ETON is 7.35, which is on the high side as it means it would take ETON, 7.35 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 7.35, ETON belongs to the best of the industry, outperforming 80.51% of the companies in the same industry.
A Debt/Equity ratio of 1.26 is on the high side and indicates that ETON has dependencies on debt financing.
ETON's Debt to Equity ratio of 1.26 is on the low side compared to the rest of the industry. ETON is outperformed by 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 7.35 | ||
| Altman-Z | 3.07 |
ROIC/WACCN/A
WACC9.86%
2.3 Liquidity
A Current Ratio of 1.77 indicates that ETON should not have too much problems paying its short term obligations.
ETON has a worse Current ratio (1.77) than 63.59% of its industry peers.
A Quick Ratio of 1.16 indicates that ETON should not have too much problems paying its short term obligations.
ETON has a Quick ratio of 1.16. This is in the lower half of the industry: ETON underperforms 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.31% over the past year.
Looking at the last year, ETON shows a very strong growth in Revenue. The Revenue has grown by 85.39%.
The Revenue has been growing by 109.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)85.39%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%108.6%
3.2 Future
The Earnings Per Share is expected to grow by 82.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, ETON will show a very strong growth in Revenue. The Revenue will grow by 42.81% on average per year.
EPS Next Y228.72%
EPS Next 2Y208.29%
EPS Next 3Y135.73%
EPS Next 5Y82.58%
Revenue Next Year107.09%
Revenue Next 2Y70.78%
Revenue Next 3Y56.05%
Revenue Next 5Y42.81%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ETON. In the last year negative earnings were reported.
ETON is valuated correctly with a Price/Forward Earnings ratio of 16.82.
ETON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ETON is cheaper than 78.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.69. ETON is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.82 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ETON is valued a bit cheaper than 75.90% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ETON is valued a bit cheaper than the industry average as 76.92% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 115.48 | ||
| EV/EBITDA | 212.78 |
4.3 Compensation for Growth
ETON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ETON's earnings are expected to grow with 135.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y208.29%
EPS Next 3Y135.73%
5. Dividend
5.1 Amount
ETON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.67
-0.2 (-1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners53.49%
Inst Owner Change18.05%
Ins Owners4.3%
Ins Owner Change-4.22%
Market Cap473.91M
Analysts82.22
Price Target30.6 (73.17%)
Short Float %13.89%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.34%
Min EPS beat(2)-167.35%
Max EPS beat(2)28.68%
EPS beat(4)2
Avg EPS beat(4)-58.34%
Min EPS beat(4)-488.82%
Max EPS beat(4)394.12%
EPS beat(8)4
Avg EPS beat(8)-38.37%
EPS beat(12)8
Avg EPS beat(12)25.01%
EPS beat(16)8
Avg EPS beat(16)-19.19%
Revenue beat(2)2
Avg Revenue beat(2)11.51%
Min Revenue beat(2)11.04%
Max Revenue beat(2)11.97%
Revenue beat(4)4
Avg Revenue beat(4)8.96%
Min Revenue beat(4)4.4%
Max Revenue beat(4)11.97%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)9
Avg Revenue beat(12)10.63%
Revenue beat(16)9
Avg Revenue beat(16)-4.79%
PT rev (1m)0%
PT rev (3m)7.23%
EPS NQ rev (1m)-18.18%
EPS NQ rev (3m)-49.06%
EPS NY rev (1m)-36.14%
EPS NY rev (3m)-65.58%
Revenue NQ rev (1m)1%
Revenue NQ rev (3m)-5.01%
Revenue NY rev (1m)2.06%
Revenue NY rev (3m)3.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 16.82 | ||
| P/S | 8.15 | ||
| P/FCF | 115.48 | ||
| P/OCF | 38.72 | ||
| P/B | 19.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 212.78 |
EPS(TTM)-0.02
EYN/A
EPS(NY)1.05
Fwd EY5.95%
FCF(TTM)0.15
FCFY0.87%
OCF(TTM)0.46
OCFY2.58%
SpS2.17
BVpS0.89
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.06% | ||
| ROE | -17.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.41% | ||
| FCFM | 7.05% |
ROA(3y)-14.67%
ROA(5y)-31.48%
ROE(3y)-30.22%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.67%
GM growth 5Y2.47%
F-Score4
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 7.35 | ||
| Debt/EBITDA | 13.34 | ||
| Cap/Depr | 306.48% | ||
| Cap/Sales | 13.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 541.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 3.07 |
F-Score4
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)372.49%
Cap/Depr(5y)366.77%
Cap/Sales(3y)13.75%
Cap/Sales(5y)36.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y228.72%
EPS Next 2Y208.29%
EPS Next 3Y135.73%
EPS Next 5Y82.58%
Revenue 1Y (TTM)85.39%
Revenue growth 3Y21.35%
Revenue growth 5Y109.79%
Sales Q2Q%108.6%
Revenue Next Year107.09%
Revenue Next 2Y70.78%
Revenue Next 3Y56.05%
Revenue Next 5Y42.81%
EBIT growth 1Y93.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year716.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.66%
OCF growth 3YN/A
OCF growth 5YN/A